Agoracom Blog Home

Author Archive

Loncor $LN.ca Announces Private Placement Financing $RSG $NGT.to $GOLD $NEM $TECK.ca

Posted by AGORACOM at 7:57 AM on Friday, January 22nd, 2021
This image has an empty alt attribute; its file name is Loncor-Small-Square.png

Loncor Resources Inc. (“Loncor” or the “Company“) (TSX: “LN”; OTCQX: “LONCF”; FSE: “LO51”) is pleased to announce a non-brokered private placement of up to 10,000,000 units of the Company (the “Units”) at a price of Cdn$0.50 per Unit for gross proceeds of up to Cdn$5,000,000 (the “Financing“). Each Unit will consist of one common share of the Company and one-half of one common share purchase warrant (each whole common share purchase warrant, a “Warrant“) of the Company, with each Warrant entitling the holder thereof to acquire one common share of the Company at an exercise price of Cdn$0.75 for a period of 12 months following the closing date of the Financing.    

About Loncor Resources Inc.
Loncor is a Canadian gold exploration company focussed on the Ngayu Greenstone Belt in the northeast of the Democratic Republic of the Congo (the “DRC”). The Loncor team has over two decades of experience of operating in the DRC. Ngayu has numerous positive indicators based on the geology, artisanal activity, encouraging drill results and an existing gold resource base. The area is 220 kilometres southwest of the Kibali gold mine, which is operated by Barrick Gold (TSX: “ABX”; NYSE: “GOLD”). In 2019, Kibali produced record gold production of 814,000 ounces at “all-in sustaining costs” of US$693/oz. Barrick has highlighted the Ngayu Greenstone Belt as an area of particular exploration interest and is moving towards earning 65% of any discovery in approximately 2,000 km2 of Loncor ground in the Ngayu Greenstone Belt that they are exploring. As per the joint venture agreements entered into between Loncor and Barrick, Barrick manages and funds exploration on the said ground until the completion of a pre-feasibility study on any gold discovery meeting the investment criteria of Barrick. In a recent announcement Barrick highlighted six prospective drill targets and have commenced confirmation drilling in 2020. Subject to the DRC’s free carried interest requirements, Barrick would earn 65% of any discovery with Loncor holding the balance of 35%. Loncor will be required, from that point forward, to fund its pro-rata share in respect of the discovery in order to maintain its 35% interest or be diluted.

In addition to the Barrick joint ventures, certain parcels of land within the Ngayu Belt surrounding and including the Adumbi and Makapela deposits have been retained by Loncor and do not form part of any of the joint ventures with Barrick. Barrick has certain pre-emptive rights over the Makapela deposit. Adumbi and two neighbouring deposits hold an inferred mineral resource of 2.5 million ounces of gold (30.65 million tonnes grading 2.54 g/t Au), with 84.68% of this resource being attributable to Loncor via its 84.68% interest in the project. Loncor’s Makapela deposit (which is 100%-owned by Loncor) has an indicated mineral resource of 614,200 ounces of gold (2.20 million tonnes grading 8.66 g/t Au) and an inferred mineral resource of 549,600 ounces of gold (3.22 million tonnes grading 5.30 g/t Au).   

Resolute Mining Limited (ASX/LSE: “RSG”) owns 26% of the outstanding shares of Loncor and holds a pre-emptive right to maintain its pro rata equity ownership interest in Loncor following the completion by Loncor of any proposed equity offering.

Read More:https://agoracom.com/ir/LoncorResources/forums/discussion/topics/753660-loncor-announces-private-placement-financing/messages/2299449#message

Beauce Gold Fields $BGF.ca Buys Missing Drill Logs Adding 344 Never Reported Drill Holes $KG.ca $OSK.ca $TIG.ca $GSR.ca $ATC.ca $WGO.ca $OR.ca $KGC.ca

Posted by AGORACOM at 9:28 AM on Thursday, January 21st, 2021
  • Acquired never before published exploration data from 1957 to 1965
  • This effectively triples the overburden drilling data that will give Beauce unprecedented overview of the placer channel

Beauce Gold Fields (TSXV: BGF) (Champs D’Or en Beauce), (“BGF”), is pleased to announce that it has acquired, from a Private Collector, a trove of never before published exploration data by the Beauce Placer Mining company that operated from 1957 to 1965 on the company’s Beauce Gold property located in Saint-Simon-les-Mines, Quebec.

Patrick Levasseur, President and CEO of Beauce Gold Fields said, “This effectively triples the overburden drilling data that will give us an unprecedented overview of the placer channel.” Mr. Levasseur added: “The data will have a profound impact in orientating our future rock drilling program to uncover the source of the gold placers.”

Figure 1: Drill Hole Map 1958, St-Gustave Road and Drill Operator

Active from 1957 to 1965, the Beauce Placer Company was the largest placer gold mining operation in eastern North America. Yet, there was very little documentation available of the work completed during that period. Historical reports found on the Government of Quebec’s geology and mining data registry are but brief summaries and observations. Missing were drill hole logs and subsequent results, geophysics data, field surveys, compilation maps and for that matter, all aspects pertaining to the dredge mining operation itself. These have now been found.

According to the Collector, the documents originated from a field office the Beauce Placer Mining Company occupied in Beauceville, Quebec. The office was abandoned in the 1970s leaving behind filing cabinets full of documents. The documents were given to the Collector, a businessman from St-Simon-les-Mine. Being an avid antiques collector, he recognized the importance of preserving historical documentation pertaining to his town’s heritage.

Document Highlights

– Total 344 drill logs from 7-inch wide overburden drill holes down to bedrock:

  • Gilbert River (St-Simon-les-Mine) – 252 holes
  • Famine River – 40 holes
  • Chaudière River – 36 holes
  • Riviere Du Loup – 12 holes
  • Ruisseau Des Meule – 4 holes

– Geophysics
– Claims and property agreements
– Land surveys
– Documentation regarding the operation of the dragline and the Yuba dredge
– Daily back office operation
– Gold receipts from the mint

Read More: https://agoracom.com/ir/BeauceGoldFields/forums/discussion/topics/753564-beauce-gold-fields-buys-missing-drill-logs-adding-344-never-reported-drill-holes/messages/2299225#message

St.George Eco Mining $SX.ca $SXOOF Appoints Paul Pelosi, Jr. Becomes President of St-Georges’ Subsidiary $NNX.ca $OM.ca $ICM.ca

Posted by AGORACOM at 2:07 PM on Wednesday, January 20th, 2021
  • Mr. Paul Pelosi, Jr. as a Director and the President of St-Georges’ new subsidiary, EVSX Corp
  • EVSX Corp is dedicated to electric vehicle battery recycling and future partnerships in the development of lithium mineral resources.

St-Georges Eco-Mining Corp. (CSE:SX)(OTC:SXOOF) (CNSX:SX.CN) (FSE:85G1) is pleased to welcome Mr. Paul Pelosi, Jr. as a Director and the President of St-Georges’ new subsidiary, EVSX Corp. which is dedicated to electric vehicle battery recycling and future partnerships in the development of lithium mineral resources.  

Paul’s expertise in green technology, eco-responsible investments, and regulatory governmental environmental legislative framework will play a critical role in developing and deploying St-Georges’ lithium mineral processing technology and EV battery recycling technology initiative.

St-Georges and its partner, Altair International, have joined forces to develop metallurgical solutions for the recycling of lithium and other metals from EV batteries.  They are working diligently to complete a long-form agreement before the end of the month.

About Paul Pelosi, Jr.

Paul Pelosi Jr. has many years of experience contributing to the sustainability of the environment through his service as President of the Environment Commission in San Francisco. The commission develops policies and programs in recycling, environmental justice, toxic reduction, energy efficiency, climate change, eco-friendly commuting alternatives, and policies regarding preserving the city’s urban forest. Paul’s experience includes emerging company investments, investment banking, sustainable real estate, and corporate governance. In each of these ventures, he was instrumental in developing corporate governance practices that advanced new technologies while supporting all stakeholders.

Paul graduated from Georgetown University with a Bachelor of Arts in History and an MBA with an emphasis in International Business. He holds a juris doctor. He is known for his humanitarian beliefs and work in the field and received the Georgetown International Human Rights Award in 1994. He has been a member of the California State Bar since 1996.

About EVSX Corp.

EVSX Corp. was recently incorporated as a wholly-owned subsidiary of St-Georges Eco-Mining Corp.  The Company will use this subsidiary to operate all research and development and hold patents and intellectual property developed within the proposed joint-venture partnership with Altair International.

Altair has the option to acquire 49.99% of the common shares of EVSX by issuing shares to St-Georges and making certain milestones payments (for more details, See Press Release “St-Georges Inks Licensing & Development Agreement for Lithium Processing Technologydated December 1, 2020)  

The Board and Management of EVSX will initially be composed of these individuals:

  • – Paul Pelosi Jr., Director & President – Mark Billings, Director & CFO – Vilhjalmur Thor Vilhjalmsson, Director – Enrico Di Cesare, Director & CEO.

Vilhjalmur Thor Vilhjalmsson,President and Chief Executive Officer of St-Georges Eco-Mining, commented, “(…) St-Georges is excited to be expanding our commitment to the environment to the recycling of lithium car batteries. Paul is the ideal candidate to be heading up this venture. He has a proven track record in promoting green technologies, which marries well with St-Georges’ core values and our deep concern for the ecosystem. We look forward to working with Paul on this and will continue to develop cutting-edge eco-green technologies for other ventures. (…)’

Harborside Inc. $HBOR.ca $HBORF Announces Upsize of Previously Announced Private Placement to C$27 Million $HBOR.ca $VFF.to $HARV.ca $ACB.to

Posted by AGORACOM at 9:39 AM on Wednesday, January 20th, 2021
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564690/hub/Harborside_Inc2_logo.png
  • Upsized its previously announced brokered private placement for gross proceeds of approximately C$27 million

Harborside Inc. (“Harborside”, or the “Company”) (CSE: HBOR), (OTCQX: HBORF), a California-focused, vertically-integrated cannabis enterprise, is pleased to announce that it has upsized its previously announced brokered private placement of units (the “Units”) of the Company at a price of C$2.55 per SVS Unit (as defined below) for gross proceeds of approximately C$27 million (the “Offering”), representing an increase of C$7 million, due to excess demand.  ATB Capital Markets and Beacon Securities Limited are co-lead agents to the Offering (the “Agents”).

The Company has granted the Agents an option to sell up to an additional 15% of the Units in the Offering, exercisable in whole or in part at any time prior to closing of the Offering.

As previously announced, Entourage Effect Capital, LLC, one of the largest shareholders of Harborside, is participating in the Offering with approximately C$9.0 million in commitment.

Read More:https://agoracom.com/ir/HarborsideInc/forums/discussion/topics/753458-harborside-inc-announces-upsize-of-previously-announced-private-placement-to-c-27-million/messages/2299033#message

Gratomic $GRAT.ca Appoints Karl Trudeau as a Director and Head of Namibian Operations $NGC.ca $LLG.ca $GPH.ca $NOU.ca $NMI.ca #TODAQ

Posted by AGORACOM at 8:51 AM on Wednesday, January 20th, 2021
  • Karl brings to the Board his unique experiences in building and operating some of the most profitable graphite mines in the Western World.

Gratomic Inc. (“GRAT” or the “Company”) (TSX.V:GRAT)(OTCQB:CBULF)(FRANKFURT:CB82)(WKN:A143MR) announces the appointment of Karl Trudeau as a Director of the Company and Head of Namibian Operations.

Karl brings to the Board his unique experiences in building and operating some of the most profitable graphite mines in the Western World. Working for Imerys Graphite et Carbonne, he operated and optimized the Lac-Des-Îles graphite mine to become the most profitable mining operation in Quebec in 2014. An additional significant milestone was achieved with Imerys, through his role as Natural Graphite Operations Leader, where Karl was responsible for the construction and development of the Okanjande Graphite Mine in Namibia, Africa.

As the COO of Nouveau Monde Graphite, Karl made important contributions to the project including his work as a pioneer in the electrification of mining operations. As the world is changing, Gratomic will be a focused leader in making the necessary and important change of establishing carbon neutral operations. Karl brings with him the knowledge from previous projects, which will assist in making the Company’s Aukam Graphite Project a carbon neutral operation.

The strength of established working relationships on previous projects with Armando Farhate and Andre Bennet and having a strong track record of delivering to plan will be a key contributing factor to the success of the Aukam Graphite Project.

“I had the privilege of working directly with Karl in other Graphite projects and having him side by side at the Board of Directors of Gratomic will ensure we continue to improve our governance level,” said Armando Farhate, COO & Head of Graphite Marketing and Sales.

“On behalf of the Board of Directors, I am very pleased to welcome Karl to the Board. This step solidifies his role with the Company and represents a harbinger of the success to come in Gratomic’s future,” said Arno Brand, President & CEO of Gratomic Inc.

The appointment of Karl Trudeau as a director is subject to the approval of the TSX Venture Exchange.

Read More: https://agoracom.com/ir/Gratomic/forums/discussion/topics/753448-gratomic-appoints-karl-trudeau-as-a-director-head-of-namibian-operations/messages/2299015#message

Harborside $HBOR.ca $HBORF Announces C$20 Million Private Placement of Equity Units and Provides 2021 Outlook $HBOR.ca $VFF.to $HARV.ca $ACB.to

Posted by AGORACOM at 6:35 PM on Tuesday, January 19th, 2021
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564690/hub/Harborside_Inc2_logo.png
  • 2020 Preliminary Results and 2021 Outlook also provided

Harborside Inc. (“Harborside”, or the “Company”) (CSE: HBOR), (OTCQX: HBORF), a California-focused, vertically-integrated cannabis enterprise, today announced a brokered private placement of units (the “Units”) of the Company (the “Offering”) at a price of C$2.55 per SVS Unit (as defined below) for gross proceeds of approximately C$20 million with approximately C$9.0 million of commitment from Entourage Effect Capital, LLC (“Entourage”), one of the largest shareholders of Harborside.

The Company has granted the Agents (as defined below) an option to sell up to an additional 15% of the Units in the Offering, exercisable in whole or in part at any time prior to closing of the Offering.

Each Unit issued to non-residents of the United States (an “SVS Unit”) will be comprised of one subordinate voting share of the Company (the “Subordinate Voting Shares”) and one Subordinate Voting Share purchase warrant (each a “Warrant”) of the Company. Each Warrant will be exercisable to acquire one Subordinate Voting Share of the Company (a “Warrant Share”) for a period of 36 months following the closing date of the Offering (the “Closing Date”) at an exercise price of C$3.69 per Warrant Share, subject to adjustment and acceleration in certain events.

All investors that are considered residents of the United States under the United States Securities Exchange Act of 1934, will be issued units comprised of multiple voting shares of the Company (the “Multiple Voting Shares”) and Multiple Voting Share purchase warrants of the Company, which will be based on the same economic equivalency of each Multiple Voting Share converting into 100 Subordinate Voting Shares.

“We are continuing to expand our footprint in the robust California cannabis market, delivering our best-in-class service and the high-quality product selection that Harborside is known for,” said Matthew Hawkins, Chairman of Harborside. “California is one of the largest cannabis markets in the world and Harborside has more than a decade of market success for our team to build on. I would like to thank our current and new shareholders for their overwhelming support of our growth strategy. This additional capital will solidify our balance sheet and provide a platform for us to continue to consolidate in the California market through accretive M&A transactions.”

Read More: https://agoracom.com/ir/HarborsideInc/forums/discussion/topics/753428-harborside-inc-announces-c-20-million-private-placement-of-equity-units-and-provides-2021-outlook/messages/2298963#message

Candente Gold Changes Name to Xali Gold Corp. $XGC.ca $FMG.ca $MEX.ca $AGI.ca $DSV.ca

Posted by AGORACOM at 6:16 PM on Monday, January 18th, 2021

Candente Gold Corp. (TSXV:CDG) (“Candente Gold” and/or the “Company”) is pleased to announce that the Company will change its name to Xali Gold Corp. on Tuesday January 19th, 2021. The new trading symbol will be XGC, CUSIP number will be 98387F103 and ISIN will be CA98387F1036. The website will also be changed to www.xaligold.com.

About Xali Gold
Xali Gold has launched a comprehensive growth strategy to build a cash flowing business platform and gain access to properties with near surface exploration potential while maintaining El Oro as its flagship asset and an integral part of the overall growth strategy. The acquisition of the SDA Plant, the El Dorado historic mines and the Cocula Project signify important initial steps.

The financial benefits from Western Mexico operations and the addition of specialized personnel will translate across platforms to strengthen the Company’s efforts to explore and potentially mine areas demonstrated to contain mineralization of value. The Company is currently evaluating other properties that are complementary to the SDA plant, El Dorado and the Cocula Project.

Read More: https://agoracom.com/ir/XaliGold/forums/discussion/topics/753330-candente-gold-changes-name-to-xali-gold-corp/messages/2298688#message

Tartisan Nickel $TN.ca: Poised For A Breakout Year! Resource Expansion & Exploration Ramp Up IS Coming IN 2021 $RNX.ca $TSLA $NOB.ca $SHL.ca $CNC.ca $FPC.ca $NICO.ca

Posted by AGORACOM at 10:33 AM on Monday, January 18th, 2021
Tc logo in black

Morgan Stanley on Nickel Forecast:

  • 6.4% demand growth in 2021
    • outpacing supply as Indo NPI growth offset by China’s decline
  • Market moving from 85kt surplus in 2020 to -18kt in ’21
    • Supporting average price of $7.29/lb, with risk skewed to bull case $8.75/lb

Tartisan Investment Highlights:

  • Kenbridge Nickel Deposit is a Class 1 Nickel project which can safely be put into production quickly at low capital cost
  • Updated Mineral Resource Estimate: 7.47 Ktonnes 0.6% Ni, 0.32% Cu open pit and underground
  • Measured and Indicated resources 985 Ktonnes Inferred at 1% Ni, 0.62% or 117 million pounds of Nickel and 66 million pounds of Copper
  • Potential to double the underground resource at Kenbridge through anticipated drill program
  • Kenbridge North – Untested Potential to Discover additional Class 1 Deposits

Tartisan Strategic Investment Holdings $9+ Million

  • Eloro Resources,  Class One Nickel and Technologies , Peruvian Metals Corp. provide Tartisan shareholders an opportunity to participate in other high-quality projects

Kenbridge Ni Project (Kenora, Ontario)

  • Property is accessible via gravel roads from paved Highway 71
  • Underground development of the deposit extends from surface to a depth of 623 metres in a 3 compartment shaft, with 244 metres of drifts and 168 metres of crosscuts at the 110 and 150 metre levels
  • The minimum drill spacing is at 15.2metres on all levels.
  • The deepest hole extends to 838.4 metre depth and intersected mineralization grading 4.25% nickel and 1.38% copper over 10.7 metres, indicating that the deposit remains open at depth.
  • Historical surface drilling was completed at 30.5metre spacing
  • Preliminary  Economic Assessment completed and updated returned robust project economics and operating costs including a NPV of C$253M and cash costs of US$3.47/lb of nickel net of copper credits

Look for Tartisan Corporate updates in 2021 at Tartisan.com

XPhyto $XPHY.ca Announces Business Strategy and Milestones For 2021 Innovation to Impact $NGM.ca $SONA.ca $HBP.ca $MIR.ca $IPA.ca

Posted by AGORACOM at 7:41 AM on Monday, January 18th, 2021
  • Commercialization of rapid COVID-19 PCR test
  • Clinical validation of transdermal and sublingual drug formulations
  • Psychedelic API production, drug formulation and clinical integration

XPhyto Therapeutics Corp. (CSE:XPHY / OTCQB:XPHYF / FSE:4XT) (“XPhyto” or the “Company“) is pleased to announce its business strategy and milestones for 2021. The Company is on the cusp of transformational change as product development programs advance from the laboratory to the clinic. As a bioscience accelerator at the leading-edge of the life science industry, XPhyto will target growth through commercialization of existing products and focused investment in impact driven innovation with the potential for extreme value creation.

The Company will continue to leverage its scientific expertise and operations in Europe and North America for product development and optimization while it plans to add significant commercial experience in the fields of manufacturing, distribution, marketing and sales. Following a successful business year 2020, XPhyto is well positioned to execute on important core milestones in all business divisions, which include the commercialization of infectious disease diagnostics, the clinical validation of transdermal and sublingual drug formulations and continued investment and development in psychedelic medicine.

Diagnostics

XPhyto’s lead diagnostic product is an accurate, rapid and highly portable PCR diagnostic test system which is secured under an exclusive global commercialization agreement from its German development partner, 3a-diagnostics GmbH (“3a”). PCR testing has emerged as the only internationally recognized standard for COVID-19 testing, which is expected to play a critical role in expediting the revitalization of many industries, particularly domestic and international travel. Successful validation of the PCR system was achieved in Q4 2020 and the Company is confident that European commercial (CE-IVD) approval will be achieved in Q1 2021. XPhyto is in discussions to secure manufacturing and distribution partners in Europe and the Middle East in anticipation of pending commercial approval and product launch in Q1 2021.

In addition to COVID-19 products, XPhyto and its partner 3a, are developing and commercializing a portfolio of low-cost oral biosensors. The Company’s lead biosensor product is an oral health screening test for the detection of peri-implantitis. There is a significant clinical need for the early detection of infection associated with dental implants prior to the onset of irreversible tissue and bone damage. The company is targeting late 2021 for European commercial approval and product launch for several biosensor screening tests.

Drug Formulations and Delivery

XPhyto’s drug formulation business is focused on neurological indications with significant market demand and the potential for meaningful patient impact. In 2020, XPhyto’s German subsidiary, Vektor Pharma TF GmbH (“Vektor”), a leader in the development of transdermal and sublingual drug formulations reported significant advancements in four therapeutic development programs. Vektor also successfully developed a sublingual drug formulation on contract for a major generic drug manufacturer and distributor.

In 2021, the Company plans to complete human pilot studies on its four lead therapeutic products: 1) Rotigotine transdermal patch for Parkinson’s disease; 2) CBD oral/sublingual strip for treatment resistant Epilepsy; 3) THC oral/sublingual strip for anorexia/nausea; and 4) CBD:THC (1:1) oral/sublingual strip for Multiple Sclerosis associated spasticity. The Company is currently in ongoing discussions with multiple potential commercial partners, licensors and distributors and will be reviewing monetization opportunities on a continued basis.

Psychedelics

Psychedelic compounds are a highly promising new class of active pharmaceutical ingredient (“API”) with strong potential for the treatment of mental health related medical conditions such as depression, anxiety, addiction, and trauma-related stress disorder. Psychedelics could provide a major improvement over currently available therapeutics for a global market with unmet medical need.

XPhyto has entered into two psychedelic agreements: first, for the development of industrial scale biotechnology processes for the production of psilocybin, and second, for research and development related to multiple psychedelic compounds, including psilocybin, mescaline, LSD, MDMA, DMT, among others.

Read More: https://agoracom.com/ir/XphytoTherapeutics/forums/discussion/topics/753246-xphyto-announces-business-strategy-and-milestones-for-2021-innovation-to-impact/messages/2298545#message

The COVID-19 Treatment Guidelines Panel’s Statement on the Use of Ivermectin for the Treatment of COVID-19 SPONSOR: Mountain Valley MD $MVMD.ca $CTLT $MRNA $NVAX

Posted by AGORACOM at 12:53 PM on Friday, January 15th, 2021

SPONSOR: Mountain Valley MD has confirmed the ability to make the drug ivermectin water-soluble without the use of organic solvents, greatly increasing the potential applications for treatment. MVMD has Improved ivermectin’s water solubility by nearly 5000 times more than current solubility  Click Here for More Info

  • The NIH has upgraded their recommendation and now consider IVERMECTIN an option for use! The national Institute of Health

Recommendation

  • The COVID-19 Treatment Guidelines Panel (the Panel) has determined that currently there are insufficient data to recommend either for or against the use of ivermectin for the treatment of COVID-19. Results from adequately powered, well-designed, and well-conducted clinical trials are needed to provide more specific, evidence-based guidance on the role of ivermectin for the treatment of COVID-19.

Rationale

Ivermectin is an antiparasitic drug that is approved by the Food and Drug Administration (FDA) for the treatment of onchocerciasis and strongyloidiasis. Ivermectin is not FDA-approved for the treatment of any viral infection. In general, the drug is well tolerated. It is currently being evaluated as a potential treatment for COVID-19.

Antiviral and Anti-Inflammatory Effects of Ivermectin

Reports from in vitro studies suggest that ivermectin acts by inhibiting the host importin alfa/beta-1 nuclear transport proteins, which are part of a key intracellular transport process that viruses hijack to enhance infection by suppressing the host antiviral response.1,2 In addition, ivermectin docking in vitro may interfere with the attachment of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein to the human cell membrane.3

Ivermectin has been shown to inhibit the replication of SARS-CoV-2 in cell culture. However, pharmacokinetic and pharmacodynamic studies suggest that ivermectin doses up to 100-fold higher than those approved for use in humans would be required to achieve the plasma concentrations necessary to duplicate the drug’s antiviral efficacy in vitro.4,5 Even though ivermectin appears to accumulate in lung tissue, with the doses used in most clinical trials, predicted systemic plasma and lung tissue concentrations are much lower than 2 µM, the half-maximal inhibitory concentration (IC50) against SARS-CoV-2 in vitro.6,7

Ivermectin demonstrates potential anti-inflammatory properties in some in vitro studies,8,9 properties which have been postulated to be beneficial in the treatment of COVID-19.10

Clinical Data

Since the last revision of the Ivermectin section of the Guidelines, the results of several randomized trials and retrospective cohort studies of ivermectin use in patients with COVID-19 have been published in peer-reviewed journals or made available as preliminary, non-peer-reviewed reports. Some clinical studies showed no benefits or worsening of disease after ivermectin use,11-14 whereas others reported shorter time to resolution of disease manifestations attributed to COVID-19,15-18 greater reduction in inflammatory markers,16,17 shorter time to viral clearance,11,16 or lower mortality rates in patients who received ivermectin than in patients who received comparator drugs or placebo.11,16,18

However, most of the studies reported to date had incomplete information and significant methodological limitations, which make it difficult to exclude common causes of bias. The missing information and limitations include the following:

  • The sample size of most of the trials was small.
  • Various doses and schedules of ivermectin were used.
  • Some of the randomized controlled trials were open-label studies in which neither the participants nor the investigators were blinded to the treatment arms.
  • In addition to ivermectin or the comparator drug, patients also received various concomitant medications (e.g., doxycycline, hydroxychloroquine, azithromycin, zinc, corticosteroids), confounding assessment of the true efficacy or safety of ivermectin.
  • The severity of COVID-19 in the study participants was not always well described.
  • The study outcome measures were not always clearly defined.

Because of these limitations, the Panel cannot draw definitive conclusions about the clinical efficacy or safety of ivermectin for the treatment of COVID-19. Results from adequately powered, well-designed, and well-conducted clinical trials are needed to provide more specific, evidence-based guidance on the role of ivermectin for the treatment of COVID-19.

SOURCE: https://www.covid19treatmentguidelines.nih.gov/statement-on-ivermectin/